JP2015175850A - インビトロアッセイにおいて凝固異常コントロール血漿として用いるための組成物 - Google Patents
インビトロアッセイにおいて凝固異常コントロール血漿として用いるための組成物 Download PDFInfo
- Publication number
- JP2015175850A JP2015175850A JP2015047974A JP2015047974A JP2015175850A JP 2015175850 A JP2015175850 A JP 2015175850A JP 2015047974 A JP2015047974 A JP 2015047974A JP 2015047974 A JP2015047974 A JP 2015047974A JP 2015175850 A JP2015175850 A JP 2015175850A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- composition
- assay
- hemostasis
- ferulic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/106664—Blood serum or blood plasma standard or control
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
種々の止血アッセイにおいて異なった抗凝血剤の効果を評価するため、異なった血漿組成物を調製した。用いたのはクエン酸塩化した正常ヒト血漿(クエン酸16mM)であり、−70℃で保存し、37℃のバスで解凍した。その後、HEPESを最終濃度40mMまで添加し、1NのNaOHを用いてpHを7.4〜7.6に調整した。種々の血漿組成物を調製した。最初の組成物には抗凝血剤は添加せず、コントロールとして用いた。分析しながら抗凝血剤の濃度を増加させて他の成分:フェルラ酸 (0.5 %, 1 % and 1.5 %), ヘパリン (0.1 IU/mL, 0.5 IU/mL and 1 IU/mL) および EDTA (0.5mg/mL, 1mg/mL, 1.5 mg/mL)に添加した。それぞれの血漿組成物を、Q 止血分析器 (Q Haemostasis Analyzer、Diagnostic Grifols, Spain)で前記PT, aPTT, TTおよびRTアッセイについてDiagnostic Grifolsの試薬DG-PT、DG-APTT Synth, DG-TT L HumanおよびGD-Fibroclotinを用いて分析した。
図1〜3は種々の抗凝血剤でのPTアッセイで得られた結果を示し、血漿中に存在する抗凝血剤の濃度の関数としてのPTアッセイで得られた時間をプロットしたものである。コントロール(抗凝血剤を含まない血漿)は三角で示し、フェルラ酸、ヘパリンおよびEDTAを含む組成物は四角で示した。フェルラ酸(図1)およびEDTA(図3)は、血漿中に存在する抗凝血剤の量に比例してPT活性の百分率が減少しているのが見られる。対照的に、ヘパリン(図2)は抗凝血剤を含まない血漿の結果と異なる結果を引き起こさなかった。これは、試験された濃度では、ヘパリンはPTアッセイに影響を及ぼさないことを意味している。一方、正常血漿に添加されたフェルラ酸とEDTAはPT活性の百分率を減少させた。
実施例1で調製したのと同じ血漿をaPPTアッセイで試験した(図4〜6)。このアッセイでは、血漿に添加した抗凝固剤、すなわち、フェルラ酸(図4)、ヘパリン(図5)およびEDTA(図6)のいずれもPTアッセイを延長した。また、アッセイの結果における延長は、血漿中に存在する抗凝血剤の量に比例している。
実施例1で調製したのと同じ血漿をTTアッセイで試験した。図7〜9は調製した血漿を試験した時のTTの結果を示す。分析した3つの抗凝血剤のうち、EDTA(図9)はアッセイの結果を延長せず、つまり、異常TTを生成しなかった。対照的に、ヘパリン(図8)およびフェルラ酸(図7)は異常TTを生成した。
実施例1で調製したのと同じ血漿をRTアッセイで試験した。RTアッセイの結果について(図10〜12)、正常血漿プールに添加した後に異常な結果を生成しなかったのはヘパリン(図11)だけだった。ヘパリンは試験したどの濃度でもRTを延長していない。抗凝血剤、フェルラ酸(図10)およびEDTA(図12)を含む血漿は異常なRT結果を生成した。
Claims (11)
- インビトロアッセイにおいて凝固異常コントロール血漿として用いるための組成物であって、ヒト血漿、緩衝された等張液およびフェルラ酸を含み、当該ヒト血漿が公知のヒト血漿抽出法で得られたものであり、緩衝された等張液のpHが6.5と8.5の間である、組成物。
- 前記ヒト血漿が、種々の凝固アッセイにおいて正常な凝固時間値を有するものである、請求項1に記載の組成物。
- 前記ヒト血漿が2以上の健常なヒトドナーからの血漿を含む正常血漿プールである、請求項1または2に記載の組成物。
- ヒト血漿の濃度が、15%(v/v)〜75%(v/v)の範囲内である、請求項1〜3のいずれか一項に記載の組成物。
- 当該等張液の量が、40%(v/v)〜70%(v/v)の範囲内である、請求項1〜4のいずれか一項に記載の組成物。
- フェルラ酸の量が、0.01%(w/v)〜1%(w/v)の範囲内である、請求項1〜5のいずれか一項に記載の組成物。
- さらに凝固因子安定剤を含む、請求項1〜6のいずれか一項に記載の組成物。
- 前記凝固因子安定剤がグリシンである、請求項7に記載の組成物。
- グリシンが、0.1%(w/v)〜4%(w/v)の量で当該組成物中に存在する、請求項8に記載の組成物。
- さらにタンパク質安定剤および防腐剤を含む、請求項1〜9のいずれか一項に記載の組成物。
- インビトロアッセイにおける異常凝固コントロールの調製におけるフェルラ酸の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201430343 | 2014-03-13 | ||
ES201430343A ES2475492B1 (es) | 2014-03-13 | 2014-03-13 | Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015175850A true JP2015175850A (ja) | 2015-10-05 |
JP6215245B2 JP6215245B2 (ja) | 2017-10-18 |
Family
ID=51063211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015047974A Active JP6215245B2 (ja) | 2014-03-13 | 2015-03-11 | インビトロアッセイにおいて凝固異常コントロール血漿として用いるための組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9482679B2 (ja) |
EP (1) | EP2919014B1 (ja) |
JP (1) | JP6215245B2 (ja) |
CN (1) | CN104914256B (ja) |
AR (1) | AR099753A1 (ja) |
AU (1) | AU2015201260B2 (ja) |
BR (1) | BR102015005628A8 (ja) |
CA (1) | CA2883260C (ja) |
CL (1) | CL2015000469A1 (ja) |
ES (2) | ES2475492B1 (ja) |
MX (1) | MX362870B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108169467B (zh) * | 2017-11-27 | 2019-09-20 | 中国科学院苏州生物医学工程技术研究所 | 一种血栓弹力图仪质控品及其制备方法和应用 |
CN109239373A (zh) * | 2018-08-15 | 2019-01-18 | 迪瑞医疗科技股份有限公司 | 一种组织因子酯化物试剂及其制备方法与应用 |
CN110346582B (zh) * | 2019-07-15 | 2022-10-25 | 三诺生物传感股份有限公司 | 一种凝血复合质控品及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10508945A (ja) * | 1994-11-13 | 1998-09-02 | ザ スクリップス リサーチ インスティテュート | 血栓性疾患の診断方法 |
WO2001007921A2 (en) * | 1999-07-23 | 2001-02-01 | Medical Analysis Systems, Inc. | Stabilized coagulation control reagent |
JP2002519703A (ja) * | 1998-07-01 | 2002-07-02 | シグマ−アルドリッチ・カンパニー | Pt、及び、aptt分析のための血液凝固コントロール |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103626653B (zh) * | 2013-08-14 | 2015-06-24 | 河南大学 | 冬凌草促凝血有效成分及其制备方法和应用 |
-
2014
- 2014-03-13 ES ES201430343A patent/ES2475492B1/es not_active Expired - Fee Related
-
2015
- 2015-02-25 CA CA2883260A patent/CA2883260C/en active Active
- 2015-02-26 CL CL2015000469A patent/CL2015000469A1/es unknown
- 2015-03-03 EP EP15382091.5A patent/EP2919014B1/en active Active
- 2015-03-03 ES ES15382091.5T patent/ES2639445T3/es active Active
- 2015-03-06 CN CN201510101355.4A patent/CN104914256B/zh active Active
- 2015-03-11 AU AU2015201260A patent/AU2015201260B2/en active Active
- 2015-03-11 JP JP2015047974A patent/JP6215245B2/ja active Active
- 2015-03-12 MX MX2015003192A patent/MX362870B/es active IP Right Grant
- 2015-03-12 US US14/656,362 patent/US9482679B2/en active Active
- 2015-03-13 AR ARP150100765A patent/AR099753A1/es active IP Right Grant
- 2015-03-13 BR BR102015005628A patent/BR102015005628A8/pt not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10508945A (ja) * | 1994-11-13 | 1998-09-02 | ザ スクリップス リサーチ インスティテュート | 血栓性疾患の診断方法 |
JP2002519703A (ja) * | 1998-07-01 | 2002-07-02 | シグマ−アルドリッチ・カンパニー | Pt、及び、aptt分析のための血液凝固コントロール |
WO2001007921A2 (en) * | 1999-07-23 | 2001-02-01 | Medical Analysis Systems, Inc. | Stabilized coagulation control reagent |
Non-Patent Citations (1)
Title |
---|
JAE JOON WEE ET AL.: "Identification of Anticoagulant Components in Korean Red Ginseng", JOURNAL OF GINSENG RESEARCH, vol. 34, no. 4, JPN6017008952, 2010, pages 355-362, XP002741001, DOI: doi:10.5142/jgr.2010.34.4.355 * |
Also Published As
Publication number | Publication date |
---|---|
BR102015005628A8 (pt) | 2022-07-05 |
CN104914256A (zh) | 2015-09-16 |
BR102015005628A2 (pt) | 2016-04-26 |
ES2639445T3 (es) | 2017-10-26 |
ES2475492A1 (es) | 2014-07-10 |
EP2919014A1 (en) | 2015-09-16 |
CA2883260C (en) | 2019-02-19 |
MX362870B (es) | 2019-02-20 |
AU2015201260A1 (en) | 2015-10-01 |
ES2475492B1 (es) | 2015-01-15 |
US20150260740A1 (en) | 2015-09-17 |
CN104914256B (zh) | 2018-04-03 |
AU2015201260B2 (en) | 2018-05-10 |
AR099753A1 (es) | 2016-08-17 |
MX2015003192A (es) | 2015-10-29 |
CA2883260A1 (en) | 2015-09-13 |
EP2919014B1 (en) | 2017-08-16 |
JP6215245B2 (ja) | 2017-10-18 |
CL2015000469A1 (es) | 2015-10-02 |
US9482679B2 (en) | 2016-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schlimp et al. | The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro | |
Görlinger et al. | Rotational thromboelastometry (ROTEM®) | |
JP5123496B2 (ja) | 血液凝固試験の標準化のための方法 | |
Abuelkasem et al. | Reduced requirement for prothrombin complex concentrate for the restoration of thrombin generation in plasma from liver transplant recipients | |
Solomon et al. | Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery | |
JP6526717B2 (ja) | 線維素溶解及び線溶亢進を検出するための方法及び試薬 | |
Solomon et al. | FIBTEM PLUS provides an improved thromboelastometry test for measurement of fibrin-based clot quality in cardiac surgery patients | |
Andersen et al. | Thromboelastometry as a supplementary tool for evaluation of hemostasis in severe sepsis and septic shock | |
Abdulrahaman et al. | Evaluation of prothrombin time and activated partial thromboplastin in patients with diabetes mellitus | |
Stegnar | Thrombophilia screening–at the right time, for the right patient, with a good reason | |
JP6215245B2 (ja) | インビトロアッセイにおいて凝固異常コントロール血漿として用いるための組成物 | |
Zipperle et al. | Point-of-care, goal-directed management of bleeding in trauma patients | |
RU2669796C1 (ru) | Способ определения функционального фибриногена | |
Genzen et al. | Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing | |
Curnow | The overall hemostatic potential (OHP) assay | |
Fabbro II et al. | Coagulation and transfusion updates from 2021 | |
Rau et al. | A calcium-containing electrolyte-balanced hydroxyethyl starch (HES) solution is associated with higher factor VIII activity than is a non-balanced HES solution, but does not affect von Willebrand factor function or thromboelastometric measurements-results of a model of in vitro haemodilution | |
Onoja et al. | Evaluation of von Willebrand factor and other coagulation homeostasis profile of patients with sickle cell anaemia attending a tertiary hospital at Enugu, Nigeria | |
Görlinger et al. | Whole blood assay: thromboelastometry–basics | |
Rutmann | Coagulation for the clinician | |
US11906532B2 (en) | Hemostasis measurement device quality control formulations | |
Meharaj | A Study on Blood Component Utilization using Thromboelastograph and Routine Coagulation Test in Liver Transplantation | |
Wilson et al. | Viscoelastometry to Manage Bleeding in Liver Disease | |
Padmanabhan et al. | Platelets in Chronic Liver Disease: Beyond Numbers | |
Peng et al. | Viscoelastic Hemostatic Tests and Fibrinogen Concentrations in Trauma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160801 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170308 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170616 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170911 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170920 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6215245 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |